1-甲基-3-吲唑羧酸甲酯 | 109216-60-6

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1-甲基-3-吲唑羧酸甲酯
• 中文别名: 1-甲基-3-吲唑甲酸甲酯；1-甲基-1H-吲唑-3-羧酸甲酯
• 英文名称: methyl 1-methyl-1H-indazole-3-carboxylate
• 英文别名: 1-Methyl-1H-indazole-3-carboxylic acid methyl ester；methyl 1-methylindazole-3-carboxylate
• CAS: 109216-60-6
• 化学式: C₁₀H₁₀N₂O₂
• mdl: MFCD03840643
• 分子量: 190.202
• InChiKey: MTCWFNXKOCOIJV-UHFFFAOYSA-N

物化性质

• 熔点：
  75-77 °C(Solv: benzene (71-43-2))
• 沸点：
  313.1±15.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少量）、DMSO（少量）、甲醇（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 1-methyl-3-indazolecarboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 1-methyl-3-indazolecarboxylate
CAS number: 109216-60-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H10N2O2
Molecular weight: 190.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-3-吲唑羧酸甲酯 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以90%的产率得到1-甲基-3-吲唑甲酸
  参考文献：
  名称：

  磺胺香豆素，香豆素，4-氨基甲酰基苯基吲哚-3-羧酰胺杂化物：肿瘤相关的碳酸酐酶同工酶IX和XII的合成和选择性抑制。

  摘要：

  针对缺氧肿瘤：合成了一系列新的含磺基香豆素，香豆素和4-氨磺酰基苯基的吲唑-3-羧酰胺杂化物，并研究了其作为人碳酸酐酶（hCA，EC 4.2.1.1）同工型I，II的抑制剂，IX和XII。这些化合物中的大多数显示出对hCA亚型IX和XII的出色效价和选择性，hCA亚型IX和XII最近已被确认为抗肿瘤药物靶标。

  DOI：

  10.1002/cmdc.201700446
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 1-甲基-3-吲唑羧酸甲酯
  参考文献：
  名称：

  v.Auwers; Stroedter, Chemische Berichte, 1926, vol. 59, p. 537

  摘要：

  DOI：

文献信息

• Exhaustive Reduction of Esters Enabled by Nickel Catalysis
  作者：Adam Cook、Sekar Prakash、Yan-Long Zheng、Stephen G. Newman

  DOI：10.1021/jacs.0c02405

  日期：2020.5.6

  tolyl-derivatives. This is achieved by an organosilane-mediated ester hydrosilylation reaction and subsequent Ni/NHC catalyzed hydrogenolysis. The resulting conditions provide a direct and efficient alternative to multi-step procedures for this transformation that often require use of hazardous metal hydrides. Applications in the synthesis of -CD3 containing products, derivatization of bioactive molecules, and chemoselective

  我们报告了将未活化的芳基酯直接还原为其相应的甲苯基衍生物的一步程序。这是通过有机硅烷介导的酯氢化硅烷化反应和随后的 Ni/NHC 催化氢解来实现的。由此产生的条件为通常需要使用危险金属氢化物的这种转化的多步骤程序提供了一种直接有效的替代方法。展示了在合成含 -CD3 的产品、生物活性分子的衍生化以及在其他 CO 键存在下进行化学选择性还原中的应用。
• CCK or gastrin modulating benzo \x9bb!\x9b1,4! diazepines derivatives
  申请人：Glaxo Wellcome Inc.

  公开号：US05859007A1

  公开（公告）日：1999-01-12

  Benzo\x9bb!\x9b1,4!diazepine compounds of formula (I), where R.sup.1 is selected from C.sub.1 C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is selected from C.sub.3 -C.sub.6 alkyl, C.sub.3 C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 alkenyl, benzyl, phenylC.sub.1 -C.sub.3 alkyl of substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl C.sub.1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R.sup.3, R.sup.5, and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkenyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR.sup.6 R.sup.7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R.sup.8 and R.sup.9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).

  以下是您提供的化学公式和描述的中文翻译： 本专利涉及1,4-苯并二氮杂卓化合物，其分子式为(I)，其中R1选自C1-C6烷基、C3-C6环烷基、苯基或取代苯基；R2选自C3-C6烷基、C3-C6环烷基、C3-C6烯基、苄基、苯基C1-C3烷基或取代苯基；或NR1R2共同形成1,2,3,4-四氢喹啉或苯并氮卓环，且单独或同时以C1-6烷基、C1-6烷氧基或卤素取代基进行单、双或三取代；p为0或1的整数；q为0或1的整数；r为0或1的整数；t为0或1的整数，条件是当r为0时，t也为0；R3、R5和R6独立地为氢或C1-6烷基；R4为C1-6烷基或C1-6烯基；R7选自氢、C1-6烷基、C1-6环烷基、C1-6烯基、苯基、取代苯基、萘基、杂芳基、取代杂芳基、双环杂芳基或取代双环杂芳基；或NR6R7共同形成一个由1,2,3或4个N、S或O杂原子隔断的饱和的5,6或7元环，条件是任意两个O或S原子不得相互连接；m为0、1、2、3或4的整数；R8和R9选自多种取代基；Z为氢或卤素；本专利还包括新颖的中间体、用于治疗肥胖、胆囊淤滞、胰腺分泌障碍的药物组合物，以及用于治疗这些疾病的方法和制备公式(I)化合物的方法。
• Copper-Catalyzed Methyl Esterification Reactions via C–C Bond Cleavage
  作者：Yan Zhu、Hong Yan、Linhua Lu、Defu Liu、Guangwei Rong、Jincheng Mao

  DOI：10.1021/jo4016387

  日期：2013.10.4

  The highly effective synthesis of methyl esters from benzylic alcohols, aldehydes, or acids via copper-catalyzed C–C cleavage from tert-butyl hydroperoxide is reported in this paper for the first time. Our protocol is easily accessible and practical, making it a possible supplement for the traditional way.

  本文首次报道了通过铜催化的氢过氧化叔丁基的铜催化CC裂解，由苄醇，醛或酸高效合成甲酯。我们的协议易于访问且实用，使其成为传统方式的可能补充。
• [EN] NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS ARYLALKYLE PYRAZOLE UTILES EN TANT QU'INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2020081381A1

  公开（公告）日：2020-04-23

  Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

  本文披露了化合物的结构式（I），这些化合物是IDO酶的抑制剂：本文还披露了这些化合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。本文还披露了包含这些化合物的组合物。此外，本文还披露了这些组合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。
• Fab I inhibitors
  申请人：Affinium Pharmaceuticals, Inc.

  公开号：US06730684B1

  公开（公告）日：2004-05-04

  Compounds of formula (I) and (II) are disclosed wherein, R1, R2, R3, R4, X, A, B, D and Q are as disclosed in the specification, and the compounds are FabI inhibitors useful in the treatment of bacterial infections.

  公式（I）和（II）的化合物已经披露，其中，R1、R2、R3、R4、X、A、B、D和Q如规范所披露，并且这些化合物是用于治疗细菌感染的FabI抑制剂。